Completed PHASE4 INTERVENTIONAL NCT00114556

The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients

The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients - A Prospective, Randomised, Controlled Clinical Trial

Sponsor: Novartis

Conditions Fractures Liver Transplantation Osteoporosis

Interventions zoledronic acid

Updated 6 times since 2017 Last updated: May 8, 2006 Started: Feb 29, 2000 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Fractures and Liver Transplantation, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2020 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Sep 2020 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Royal Prince Alfred Hospital, Sydney, Australia

Data source: Royal Prince Alfred Hospital, Sydney, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia